SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:umu-124505"
 

Sökning: onr:"swepub:oai:DiVA.org:umu-124505" > Introduction and Ut...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005768naa a2200913 4500
001oai:DiVA.org:umu-124505
003SwePub
008160815s2016 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:133934247
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1245052 URI
0247 a https://doi.org/10.3389/fphar.2016.001972 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1339342472 URI
040 a (SwePub)umud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a de Bruijn, Winnie4 aut
2451 0a Introduction and Utilization of High Priced HCV Medicines across Europe :b Implications for the Future
264 c 2016-07-22
264 1b Frontiers Media SA,c 2016
338 a electronic2 rdacarrier
520 a Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (Hs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens. Objective: Assess the uptake of BCV and TVR across Europe from a health authority perspective to offer future guidance on dealing with new high cost medicines. Methods: Cross-sectional descriptive study of medicines to treat HCV (pegIEN, ribavirin, BCV and TVR) among European countries from 2008 to 2013. Utilization measured in defined daily doses (DDDs)/1000 patients/quarter (DIOs) and expenditure in Euros/DDD. Health authority activities to influence treatments categorized using the 4E methodology (Education, Engineering, Economics and Enforcement). Results: Similar uptake of BCV and TVR among European countries and regions, ranging from 0.5 DIQ in Denmark, Netherlands and Slovenia to 1.5 DIQ in Tayside and Catalonia in 2013. However, different utilization of the new Pls vs. ribavirin indicates differences in dual vs. triple therapy, which is down to factors including physician preference and genotypes. Reimbursed prices for BCV and TVR were comparable across countries. Conclusion: There was reasonable consistency in the utilization of BCV and TVR among European countries in comparison with other high priced medicines. This may reflect the social demand to limit the transmission of HCV. However, the situation is changing with new curative medicines for HCV genotype 1 (GT1) with potentially an appreciable budget impact. These concerns have resulted in different prices across countries, with their impact on budgets and patient outcomes monitored in the future to provide additional guidance.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng
653 a boceprevir
653 a cross national drug utilization study
653 a demand-side measures
653 a Hepatitis C
653 a introduction new medicines
653 a sofosbuvir
653 a telaprevir
7001 a Ibanez, Cristina4 aut
7001 a Frisk, Pia4 aut
7001 a Pedersen, Hanne Bak4 aut
7001 a Alkan, Ali4 aut
7001 a Bonanno, Patricia Vella4 aut
7001 a Brkicic, Ljiljana S.4 aut
7001 a Bucsicsa, Anna4 aut
7001 a Dedet, Guillaume4 aut
7001 a Eriksen, Jaranu Karolinska Institutet4 aut
7001 a Fadare, Joseph O.4 aut
7001 a Furst, Jurij4 aut
7001 a Gallego, Gisselleu Umeå universitet,Klinisk neurovetenskap,School of Medicine, The University of Notre Dame Australia, Darlinghurst, NSW, Australia4 aut0 (Swepub:umu)giga0007
7001 a Godoi, Isabella P.4 aut
7001 a Guerra Junior, Augusto A.4 aut
7001 a Gursoz, Hakki4 aut
7001 a Jan, Saira4 aut
7001 a Jones, Jan4 aut
7001 a Joppi, Roberta4 aut
7001 a Kerman, Saim4 aut
7001 a Laius, Ott4 aut
7001 a Madzikwa, Newman4 aut
7001 a Magnusson, Einar4 aut
7001 a Maticic, Mojca4 aut
7001 a Markovic-Pekovic, Vanda4 aut
7001 a Massele, Amos4 aut
7001 a Ogunleye, Olayinka4 aut
7001 a O'Leary, Aisling4 aut
7001 a Piessnegger, Jutta4 aut
7001 a Sermet, Catherine4 aut
7001 a Simoens, Steven4 aut
7001 a Tiroyakgosi, Celda4 aut
7001 a Truter, Ilse4 aut
7001 a Thyberg, Magnus4 aut
7001 a Tomekova, Kristina4 aut
7001 a Wladysiuk, Magdalena4 aut
7001 a Vandoros, Sotiris4 aut
7001 a Vural, Elif H.4 aut
7001 a Zara, Corinne4 aut
7001 a Godman, Brianu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Klinisk neurovetenskap4 org
7730 t Frontiers in Pharmacologyd : Frontiers Media SAg 7q 7x 1663-9812
8564 u https://doi.org/10.3389/fphar.2016.00197y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:954252/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://www.frontiersin.org/articles/10.3389/fphar.2016.00197/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-124505
8564 8u https://doi.org/10.3389/fphar.2016.00197
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:133934247

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy